Evidence map›Paper›PMID 39885298›Full record

ArticleMolecular psychiatry2025

Synaptic vulnerability to amyloid-β and tau pathologies differentially disrupts emotional and memory neural circuits.

Maria Dolores Capilla-López, Angel Deprada, Yuniesky Andrade-Talavera, Irene Martínez-Gallego, Heriberto Coatl-Cuaya, Paula Sotillo, José Rodríguez-Alvarez, Antonio Rodríguez-Moreno, Arnaldo Parra-Damas, Carlos A Saura

Abstract read
In one paragraph

Article in Molecular psychiatry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Neurotransmitter Systems in Alzheimer's Disease.Current issues in molecular biology · 2026
    Review
  5. Article
  6. Review
  7. Frontiers in medicine · 2026
    Article
  8. Article
  9. Review
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Maria Dolores Capilla-LópezInstitut de Neurociències, Department de Bioquímica i Biologia Molecular, Facultat de Medicina, Universitat Autònoma de Barcelona, Bellaterra, Barcelona, Spain.ORCID 0000-0002-9483-4887
Angel DepradaInstitut de Neurociències, Department de Bioquímica i Biologia Molecular, Facultat de Medicina, Universitat Autònoma de Barcelona, Bellaterra, Barcelona, Spain.ORCID 0000-0002-7860-6307
Yuniesky Andrade-TalaveraDepartment of Physiology, Anatomy and Cell Biology, Universidad Pablo de Olavide, Sevilla, Spain.ORCID 0000-0002-5295-0169
Irene Martínez-GallegoDepartment of Physiology, Anatomy and Cell Biology, Universidad Pablo de Olavide, Sevilla, Spain.ORCID 0000-0002-8936-8201
Heriberto Coatl-CuayaDepartment of Physiology, Anatomy and Cell Biology, Universidad Pablo de Olavide, Sevilla, Spain.ORCID 0000-0003-4953-6562
Paula SotilloInstitut de Neurociències, Department de Bioquímica i Biologia Molecular, Facultat de Medicina, Universitat Autònoma de Barcelona, Bellaterra, Barcelona, Spain.ORCID 0009-0005-9320-5949
José Rodríguez-AlvarezInstitut de Neurociències, Department de Bioquímica i Biologia Molecular, Facultat de Medicina, Universitat Autònoma de Barcelona, Bellaterra, Barcelona, Spain.ORCID 0000-0001-8582-8082
Antonio Rodríguez-MorenoDepartment of Physiology, Anatomy and Cell Biology, Universidad Pablo de Olavide, Sevilla, Spain.ORCID 0000-0002-8078-6175
Arnaldo Parra-DamasInstitut de Neurociències, Department de Bioquímica i Biologia Molecular, Facultat de Medicina, Universitat Autònoma de Barcelona, Bellaterra, Barcelona, Spain. arnaldo.parra@uab.cat.ORCID 0000-0001-5683-060X
Carlos A SauraInstitut de Neurociències, Department de Bioquímica i Biologia Molecular, Facultat de Medicina, Universitat Autònoma de Barcelona, Bellaterra, Barcelona, Spain. carlos.saura@uab.cat.ORCID 0000-0003-3692-5657

Funding

BrightFocus Foundation (BrightFocus) A2022047SDepartament d'Innovació, Universitats i Empresa, Generalitat de Catalunya (Department of Innovation, Education and Enterprise, Government of Catalonia) 2021 SGR00142EC | EU Framework Programme for Research and Innovation H2020 | H2020 Priority Excellent Science | H2020 Marie Skłodowska-Curie Actions (H2020 Excellent Science - Marie Skłodowska-Curie Actions) GA. 101061171
6 · The paper itself

Abstract

Alzheimer's disease (AD) is characterized by memory loss and neuropsychiatric symptoms associated with cerebral amyloid-β (Aβ) and tau pathologies, but whether and how these factors differentially disrupt neural circuits remains unclear. Here, we investigated the vulnerability of memory and emotional circuits to Aβ and tau pathologies in mice expressing mutant human amyloid precursor protein (APP), Tau or both APP/Tau in excitatory neurons. APP/Tau mice develop age- and sex-dependent Aβ and phosphorylated tau pathologies, the latter exacerbated at early stages, in vulnerable brain regions. Early memory deficits were associated with hippocampal tau pathology in Tau and APP/Tau mice, whereas anxiety and fear appeared linked to intracellular Aβ in the basolateral amygdala (BLA) of APP and APP/Tau mice. Transcriptome hippocampal profiling revealed gene changes affecting myelination and RNA processing in Tau mice, and inflammation and synaptic-related pathways in APP/Tau mice at 6 months. At 9 months, we detected common and region-specific changes in astrocytic, microglia and 63 AD-associated genes in the hippocampus and BLA of APP/Tau mice. Spatial learning deficits were associated with synaptic tau accumulation and synapse disruption in the hippocampus of Tau and APP/Tau mice, whereas emotional disturbances were linked to Aβ pathology but not synaptic tau in the BLA. Interestingly, Aβ and tau exhibited synergistic detrimental effects in long-term potentiation (LTP) in the hippocampus but they counteract with each other to mitigate LTP impairments in the amygdala. These findings indicate that Aβ and tau pathologies cause region-specific effects and synergize to induce synaptic dysfunction and immune responses, contributing to the differing vulnerability of memory and emotional neural circuits in AD.

Indexed as

Amyloid beta-PeptidesMemory Disorderstau ProteinsAlzheimer DiseaseAmygdalaAmyloid beta-Protein PrecursorAnimalsBasolateral Nuclear ComplexBrainDisease Models, AnimalEmotionsFearFemaleHippocampusHumansMaleAmyloid beta-PeptidesAmyloid beta-Protein Precursortau Proteins

Identifiers

PMID39885298
PMCPMC12185336

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.